New research could help dogs with a common cancer get better treatment and help save lives

Research conducted by a team of scientists and vets at the Animal Health Trust, in collaboration with the University of Liverpool, offers new hope to vets and dog owners.

Cutaneous mast cell tumours are the most common form of skin cancer in dogs. Aggressive forms of these tumours often recur, or spread to local lymph nodes, the liver and/or spleen and can cause death within a year.

Currently vets do not have a test that will accurately predict if a dog’s cutaneous mast cell tumour will spread or not. Chemotherapy is used to slow mast cell tumour spread, but there is no treatment that can stop the tumours from spreading and affected dogs from dying prematurely.

The Animal Health Trust’s research, led by Dr Mike Starkey and recently published in the scientific journal PLOS ONE, has successfully identified genetic changes in cutaneous mast cell tumours that are linked to tumour spread. This information may eventually be used by vets to better determine how best to treat dogs with mast cell tumours, and may also promote the development of new treatments.

Leading on from this discovery, it will hopefully be possible – for the first time – to develop a non-invasive prognostic test which will accurately tell vets if a cutaneous mast cell tumour is likely to spread, and therefore if chemotherapy is appropriate.

The availability of such a test would help to ensure that dogs affected by this type of cancer receive the right treatment, and would reduce the number of dogs who unnecessarily receive treatment that is not beneficial. In addition, the results of the research could promote the trials of new anti-tumour spread drugs in dogs affected by mast cell tumours predicted to spread.

Dr Mike Starkey said: “The findings of the research study is the result of many years work and are important because so many dogs are affected by cutaneous mast cell tumours. Cancer affects 1 in 4 dogs and research is the only way to fight cancer. I’m hugely grateful to everyone who has supported my team and this research to-date, and I believe this is a really exciting time as we can begin to see how our work can improve the outcome for dogs with cancer.

“We spent a lot of time collecting a suitable group of mast cell tumour samples to allow us to study tumour spread, but we are very excited about the results and their potential relevance to dog health. A further validation study on a larger scale is required to demonstrate that focussing on a small number of the genetic changes linked to tumour spread can consistently accurately predict if a cutaneous mast cell tumour will spread. However, we are optimistic that with the help of vets all over the country we can collect the necessary tumour samples, and complete the study within two years, and be ready to start developing a prognostic test during 2021.

“The Animal Health Trust is the only charity with a dedicated canine cancer research group in the UK. Significantly, anything we learn about a cancer in dogs may help understanding of the corresponding cancer in humans.”

This research was made possible due to extensive charitable funding, most notably from the Kennel Club Charitable Trust, which funded the ‘GeneAtlas System’ which enabled Dr Mike Starkey’s team to analyse the genetic blueprints of the mast cell tumours at the Animal Health Trust. The research team is also privileged to be supported by Zoe’s Journey UK.

Steve Dean, Chairman of the Kennel Club Charitable Trust, said: “Discovering that your dog has been diagnosed with cancer is an extremely emotional time in any dog owner’s life, and our support for cancer research at the Animal Health Trust is vital in helping to make that journey a bit easier for dog owners in the future.

“Knowing that the veterinary surgeons treating your dog have the tools at their disposal to be able to predict whether or not a mast cell tumour will spread will be very reassuring for those wishing to give their dog the best chance of survival. Being able to ensure that their dog gets the most appropriate treatment will be a positive benefit too and we hope that this research is a first important step towards delivering useful prognostic tests for this common cancer.

“It is heartening to know that the purchase of the GeneAtlas system at the Animal Health Trust, which the Kennel Club Charitable Trust funded, is proving so important in this research. The data collected during this research has enabled the analysis of tumour genetics and improved our understanding of canine cancer. The development of accurate tests will be an exciting development for the future.”

For more information about this research, further research or to donate to help the Animal Health Trust research cancer in dogs, go to: www.aht.org.uk/research/cancer

 

More information about the research and discovery

Click here to read the paper published in PLOS ONE on 19 December 2018.

The retrospective study compared the genetic blueprints of 20 primary cutaneous canine mast cell tumours which spread (metastasised) and 20 that did not, and identified over 200 genes associated with mast cell tumour metastasis. Measuring the levels of 19 of these genes in a mast cell tumour could be used to identify a tumour that spread with an accuracy of 90 – 100 per cent, and a tumour that didn’t spread with an accuracy of 70 – 100 per cent.

In the absence of an accurate test for predicting if a mast cell tumour will metastasise, dogs that may benefit from chemotherapy may not receive the treatment, and dogs that would be cured by surgery and/or radiotherapy alone may unnecessarily receive chemotherapy. In addition, chemotherapy does not prevent metastasis or a premature death due to mast cell tumour metastatic disease.

The research results lay the foundations for an accurate prognostic test which could be run on a mast cell tumour fine needle aspirate, and would predict whether a dog had a metastasising mast cell tumour and would therefore potentially benefit from chemotherapy. In addition, by identifying changes to genes that enable mast cell tumour metastasis, these results could promote the trials of anti-metastasis drugs in dogs affected by mast cell tumours predicted to metastasise.

This study was a collaboration between the Animal Health Trust and the University of Liverpool, and featured biopsies of mast cell tumours from patients of the AHT’s Centre for Small Animal Studies and University of Liverpool Small Animal Teaching Hospital clinical oncology units.

Next step

The next step will be to further validate the accuracy of these results by conducting a larger retrospective study. In order to do this, the Animal Health Trust will need to recruit in the region of 100 mast cell tumour biopsies from dogs with a detailed clinical history in order to ensure that it is clear whether a tumour metastasised. Collecting the 40 mast cell tumour biopsies for the first study proved difficult and so the Animal Health Trust is keen to highlight to vets the challenges with this type of research and how they can help.

The validation study will potentially enable a reduction in the number of genes whose levels in a mast cell tumour need to be measured in order to accurately predict whether a tumour will spread, making a prognostic test easier to run and reducing the cost. It is hoped that the next study can be completed within two years and work to develop the prognostic test could start as early as 2021.